Biotec Pharmacon ASA

Contact

About Biotec Pharmacon

Biotec Pharmacon develops, manufactures, and markets immune modulating compounds and molecular biology grade enzymes, based on own research in immunology and marine biotechnology.

Product portfolio of Biotec Pharmacon

Product portfolio

Show all

News about Biotec Pharmacon

19-Jul-2011 | research and development

Biotec Pharmacon reports on neuroblastoma study

Biotec Pharmacon ASA is announcing the final results from an early phase (I/II) study on combining Soluble Beta-Glucan (SBG) with anti-cancer antibodies in ...

Read news

27-Jan-2011 | research and development

Biotec Pharmacon receives promising interim results from animal study

Biotec Pharmacon ASA has received an interim data report from the second animal study in diabetic mice. The results confirm the finding from the first ...

Read news

12-Mar-2010 | people

Svein Lien appointed new CEO of Biotec Pharmacon ASA

Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen's decision to resign after 3 years as CEO. Svein Lien will assume the ...

Read news

24-Nov-2009 | research and development

Biotec Pharmacon: Phase III results with SBG for diabetic foot ulcer not positive

Biotec Pharmacon has received the results from both its phase III studies with SBG for diabetic foot ulcer and regrets to inform that the results are not ...

Read news

18-Jun-2009 | business & finance

Jan Buch Andersen heading up newly established Biotec Marine Biochemicals AS

Biotec Pharmacon ASA has moved all its enzyme activities into Biotec Marine Biochemicals AS and hired Jan Buch Andersen as Managing Director of the newly ...

Read news

15-May-2009 | research and development

Biotec Pharmacon: Phase III diabetic ulcer program proceeds as planned after interim analysis

The independent statistician responsible for the interim analysis of the second of the two phase III studies with SBG for diabetic foot ulcers recommends ...

Read news

27-Mar-2009 | research and development

Biotec Pharmacon's SBG shows promising effect in animal model for inflammatory bowel disease

Researchers at Rikshospitalet University Hospital has presented an abstract from an animal study with SBG for treatment of inflammatory bowel disease on ...

Read news

20-Oct-2008 | price development

Biotec Pharmacon: Patient inclusion started in phase III Oral Mucositis study

Patient inclusion has commenced as planned in the first of two phase III studies for the use of Biotec Pharmacon's SBG in patients with oral mucositis. ...

Read news

Show more news about Biotec Pharmacon

Biotec Pharmacon ASA

About Biotec Pharmacon

Product portfolio of Biotec Pharmacon

Product portfolio

Merck Life Science KGaA

Jena Bioscience GmbH

News about Biotec Pharmacon

Biotec Pharmacon reports on neuroblastoma study

Biotec Pharmacon receives promising interim results from animal study

Svein Lien appointed new CEO of Biotec Pharmacon ASA

Biotec Pharmacon: Phase III results with SBG for diabetic foot ulcer not positive

Jan Buch Andersen heading up newly established Biotec Marine Biochemicals AS

Biotec Pharmacon: Phase III diabetic ulcer program proceeds as planned after interim analysis

Biotec Pharmacon's SBG shows promising effect in animal model for inflammatory bowel disease

Biotec Pharmacon: Patient inclusion started in phase III Oral Mucositis study

Here you will find Biotec Pharmacon ASA